Loading...
•
Sep 30, 2023
Y-mAbs Q3 2023 Earnings Report
Y-mAbs reported a net product revenue of $20.0 million from DANYELZA and a net loss of $7.7 million for the third quarter of 2023.
Key Takeaways
Y-mAbs Therapeutics, Inc. reported a 59% increase in DANYELZA net product sales, reaching $20 million in Q3 2023 compared to the same period in 2022. The company's total revenues increased by 63% to $20.5 million. They also reported a net loss of $7.7 million, significantly lower than the $27.5 million loss in Q3 2022. With $86.6 million in cash and cash equivalents, Y-mAbs anticipates funding operations into 2027.
DANYELZA net product revenues reached $20.0 million, a 59% increase compared to Q3 2022.
Total revenues increased by 63% to $20.5 million, including $0.5 million in license revenue.
Net loss decreased to $7.7 million, compared to a net loss of $27.5 million in Q3 2022.
Cash and cash equivalents totaled $86.6 million, expected to support operations into 2027.
Revenue by Geographic Location
Forward Guidance
The company is updating and reiterating its full-year 2023 financial guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...